BAT1308 / Bio-Thera Solutions 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Avzivi (bevacizumab-tnjn) - Bio / Thera Solutions, Cipla, BeiGene, Biomm, Mega Lifesciences, Sandoz, BAT1308 - Bio / Thera Solutions
    New P2/3 trial, Metastases:  BAT1308 Combined With Platinum-Based Chemotherapy (clinicaltrials.gov) -  Nov 8, 2023   
    P2/3,  N=526, Not yet recruiting, 
  • ||||||||||  BAT6021 - Bio / Thera Solutions, BAT1308 - Bio / Thera Solutions
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients (clinicaltrials.gov) -  Oct 11, 2023   
    P1,  N=13, Terminated, 
    Not yet recruiting --> Recruiting N=29 --> 13 | Trial completion date: Jun 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2023; Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline.
  • ||||||||||  BAT6026 - Bio / Thera Solutions, BAT1308 - Bio / Thera Solutions
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients (clinicaltrials.gov) -  May 1, 2023   
    P1,  N=13, Terminated, 
    N=29 --> 13 | Trial completion date: Jun 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2023; Based on the disclosed global research data on the same target drugs, the company has carefully considered and decided to terminate the project to optimize the existing research pipeline. N=29 --> 13 | Trial completion date: Dec 2024 --> Mar 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Mar 2023; Considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily
  • ||||||||||  BAT6021 - Bio / Thera Solutions, BAT1308 - Bio / Thera Solutions
    Trial primary completion date, Combination therapy, Metastases:  Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients (clinicaltrials.gov) -  Mar 17, 2023   
    P1,  N=29, Recruiting, 
    N=29 --> 13 | Trial completion date: Dec 2024 --> Mar 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Mar 2023; Considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily Trial primary completion date: Oct 2022 --> Oct 2023